In this post-hoc analysis of the SURMOUNT-1 trial, there was a mostly linear relationship between percentage change in weight ...

1. Median overall survival was 13.6 months in the tarlatamab group and 8.3 months in the chemotherapy group, with HR 0.60 (significant) 2. Adverse events grade 3 or higher occurred in 54% of the ...

Reductions in pain catastrophizing are more closely associated with improvements in emotional functioning than with pain ...